Xenon Pharmaceuticals Inc. - 8-K Filing
Xenon Pharmaceuticals Inc. filed this Form 8-K on June 2, 2026, to report that shareholders approved the company's 2026 Equity Incentive Plan at its annual meeting. The plan replaces the Amended and Restated 2014 Equity Incentive Plan and authorizes up to 4,400,000 common shares for awards under the new plan, plus additional shares from expired or forfeited grants in the existing plan (capped at a total of 14,720,800). Shareholders also elected seven directors with over 93% voting participation and approved advisory votes on executive compensation and auditor remuneration. (Items: 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Offi, 5.07 below, upon the recommendation of the Board of Directors (the “Board”) of Xenon Pharmaceuticals Inc, 9.01 Financial Statements and Exhibits)
Tickers: $XENE